Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2010

01-05-2010 | Research Paper

Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice

Authors: Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi, Shinsaku Otsuka, Hirokazu Ogino, Soji Kakiuchi, Hisanori Uehara, Seiji Yano, Yasuhiko Nishioka, Saburo Sone

Published in: Clinical & Experimental Metastasis | Issue 5/2010

Login to get access

Abstract

Lung cancer frequently develops multiple organ metastases, which thus makes this disease a leading cause of malignancy-related death worldwide. A gender difference is reported to affect the incidence and mortality of lung cancer; however, whether and how the gender difference is involved in lung cancer metastasis is unclear. This study evaluated the gender difference in multiple organ metastases in human small cell lung cancer (SBC-5) cells by using natural killer cell-depleted severe combined immunodeficient mice. Among multiple organ metastases, only bone metastasis formation significantly increased in female mice in comparison to males, while no significant difference was observed in the metastases to the liver and lungs. The suppression of androgen by castration or androgen receptor antagonist treatment in male mice also induced a significant increase of bone metastases. The number of osteoclasts in the bone metastatic lesions was greater in female mice and in mice with androgen suppression than in control male. However, there was no significant difference in the serum concentration of parathyroid hormone-related protein (PTHrP) associated with gender or androgen suppression. An in vitro study also indicated that sex steroid treatment had no effect on the proliferation or PTHrP production in SBC-5 cells. These results indicate that the balance of sex steroids therefore plays an important role in the formation of bone metastasis in small cell lung cancer, and suggests diverse mechanisms of interaction between cancer cells and host cells in the bone microenvironment.
Literature
1.
go back to reference Sone S, Yano S (2007) Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev 26:685–689CrossRefPubMed Sone S, Yano S (2007) Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev 26:685–689CrossRefPubMed
2.
go back to reference Vicent S, Luis-Ravelo D, Antón I et al (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 68:2275–2285CrossRefPubMed Vicent S, Luis-Ravelo D, Antón I et al (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 68:2275–2285CrossRefPubMed
3.
go back to reference Jemal A, Thun MJ, Ries L et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefPubMed Jemal A, Thun MJ, Ries L et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefPubMed
4.
go back to reference Ou SH, Ziogas A, Zell JA et al (2009) Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43CrossRefPubMed Ou SH, Ziogas A, Zell JA et al (2009) Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43CrossRefPubMed
5.
go back to reference Asamura H, Goya T, Koshiishi Y et al (2008) A Japanese lung cancer registry study: prognosis of 13, 010 resected lung cancers. J Thorac Oncol 3:46–52CrossRefPubMed Asamura H, Goya T, Koshiishi Y et al (2008) A Japanese lung cancer registry study: prognosis of 13, 010 resected lung cancers. J Thorac Oncol 3:46–52CrossRefPubMed
6.
go back to reference Dongiovanni D, Daniele L, Barone C et al (2008) Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer 61:73–81CrossRefPubMed Dongiovanni D, Daniele L, Barone C et al (2008) Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer 61:73–81CrossRefPubMed
7.
go back to reference Niikawa H, Suzuki T, Miki Y et al (2008) Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14:4417–4426CrossRefPubMed Niikawa H, Suzuki T, Miki Y et al (2008) Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14:4417–4426CrossRefPubMed
8.
go back to reference Nishio M, Ohyanagi F, Horiike A et al (2005) Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. Br J Cancer 92:1877–1880CrossRefPubMed Nishio M, Ohyanagi F, Horiike A et al (2005) Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. Br J Cancer 92:1877–1880CrossRefPubMed
9.
go back to reference Montgrain PR, Quintana R, Rascon Y et al (2007) Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer. Cancer 110:1313–1320CrossRefPubMed Montgrain PR, Quintana R, Rascon Y et al (2007) Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer. Cancer 110:1313–1320CrossRefPubMed
10.
go back to reference Miki T, Yano S, Hanibuchi M et al (2004) Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice. Int J Cancer 108:511–515CrossRefPubMed Miki T, Yano S, Hanibuchi M et al (2004) Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice. Int J Cancer 108:511–515CrossRefPubMed
11.
go back to reference Mohla S, Weilbacher KN, Cher ML et al (2003) Third North American symposium on skeletal complications of malignancy: summary of the scientific sessions. Cancer 97:719–725CrossRefPubMed Mohla S, Weilbacher KN, Cher ML et al (2003) Third North American symposium on skeletal complications of malignancy: summary of the scientific sessions. Cancer 97:719–725CrossRefPubMed
12.
go back to reference Tsuya A, Fukuoka M (2008) Bone metastasis in lung cancer. Club Calcium 18:455–459 Tsuya A, Fukuoka M (2008) Bone metastasis in lung cancer. Club Calcium 18:455–459
14.
go back to reference Coleman RE, Guise TA, Lipton A et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14:6387–6395CrossRefPubMed Coleman RE, Guise TA, Lipton A et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14:6387–6395CrossRefPubMed
15.
go back to reference Matsumoto C, Inada M, Toda K et al (2006) Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone 38:220–226CrossRefPubMed Matsumoto C, Inada M, Toda K et al (2006) Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone 38:220–226CrossRefPubMed
16.
go back to reference Yamada Y, Takahashi S, Fujimura T et al (2008) The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporos Int 19:321–327CrossRefPubMed Yamada Y, Takahashi S, Fujimura T et al (2008) The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporos Int 19:321–327CrossRefPubMed
17.
go back to reference Allan G, Lai MT, Sbriscia T et al (2007) A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 103:76–83CrossRefPubMed Allan G, Lai MT, Sbriscia T et al (2007) A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 103:76–83CrossRefPubMed
18.
go back to reference Fukusato T, Aoyama H, Mori W (1989) Age and sex differences in bone metastasis of hepatocellular carcinoma in Japanese autopsy cases. Gastroenterol Jpn 24:127–134PubMed Fukusato T, Aoyama H, Mori W (1989) Age and sex differences in bone metastasis of hepatocellular carcinoma in Japanese autopsy cases. Gastroenterol Jpn 24:127–134PubMed
19.
go back to reference Funk JL, Wei H (1998) Regulation of parathyroid hormone-related protein expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Biochem Biophys Res Commun 251:849–854CrossRefPubMed Funk JL, Wei H (1998) Regulation of parathyroid hormone-related protein expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Biochem Biophys Res Commun 251:849–854CrossRefPubMed
20.
go back to reference Rabbani SA, Khalili P, Arakelian A et al (2005) Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 146:2885–2894CrossRefPubMed Rabbani SA, Khalili P, Arakelian A et al (2005) Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 146:2885–2894CrossRefPubMed
21.
go back to reference Pizzi H, Gladu J, Carpio L et al (2003) Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology 144:858–867CrossRefPubMed Pizzi H, Gladu J, Carpio L et al (2003) Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology 144:858–867CrossRefPubMed
22.
go back to reference Zhau HY, Chang SM, Chen BQ et al (1996) Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93(26):15152–15157CrossRefPubMed Zhau HY, Chang SM, Chen BQ et al (1996) Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93(26):15152–15157CrossRefPubMed
23.
go back to reference Martinez J, Fuentes M, Cambiazo V et al (1999) Bone extracellular matrix stimulates invasiveness of estrogen-responsive human mammary MCF-7 cells. Int J Cancer 83(2):278–282CrossRefPubMed Martinez J, Fuentes M, Cambiazo V et al (1999) Bone extracellular matrix stimulates invasiveness of estrogen-responsive human mammary MCF-7 cells. Int J Cancer 83(2):278–282CrossRefPubMed
24.
25.
go back to reference Montgrain PR, Quintana R, Rascon Y et al (2007) Parathyroid hormone-related protein caries with sex and androgen status in nonsmall cell lung cancer. Cancer 110(6):1313–1320CrossRefPubMed Montgrain PR, Quintana R, Rascon Y et al (2007) Parathyroid hormone-related protein caries with sex and androgen status in nonsmall cell lung cancer. Cancer 110(6):1313–1320CrossRefPubMed
26.
go back to reference Bellido T, Jilka RL, Boyce BF (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95(6):2886–2895CrossRefPubMed Bellido T, Jilka RL, Boyce BF (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95(6):2886–2895CrossRefPubMed
Metadata
Title
Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice
Authors
Satoshi Sakaguchi
Hisatsugu Goto
Masaki Hanibuchi
Shinsaku Otsuka
Hirokazu Ogino
Soji Kakiuchi
Hisanori Uehara
Seiji Yano
Yasuhiko Nishioka
Saburo Sone
Publication date
01-05-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9333-0

Other articles of this Issue 5/2010

Clinical & Experimental Metastasis 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine